Latest news with #ROSA
Globe and Mail
14-07-2025
- Business
- Globe and Mail
Zimmer Biomet Announces Definitive Agreement to Acquire Monogram Technologies, Expanding Robotics Suite with Autonomous Solutions
Proposed transaction creates the broadest, most flexible portfolio of orthopedic robotics and navigation technologies to meet surgeons' needs Acquisition expected to be neutral to adjusted earnings per share in 2025 – 2027 and accretive thereafter and to contribute to revenue growth beginning in 2027 WARSAW, Indiana and AUSTIN, Texas, July 14, 2025 (GLOBE NEWSWIRE) -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and Monogram Technologies Inc. (NASDAQ: MGRM), an orthopedic robotics company, today announced they have entered into a definitive agreement for Zimmer Biomet to acquire all outstanding shares of stock of Monogram for an upfront payment of $4.04 per share in cash, corresponding to an equity value of approximately $177 million and an enterprise value of approximately $168 million. Monogram common stockholders will also receive a non-tradeable contingent value right (CVR) entitling the holder to receive up to $12.37 per share of common stock in cash if certain product development, regulatory and revenue milestones are achieved through 2030. The respective boards of directors of Zimmer Biomet and Monogram have unanimously approved the proposed transaction. Monogram's semi- and fully autonomous robotic technologies are expected to add new and differentiated capabilities to expand Zimmer Biomet's flagship ROSA ® Robotics platform and broad suite of navigation and enabling technologies. Monogram has developed a CT-based, semi-autonomous, AI-navigated total knee arthroplasty (TKA) robotic technology, which received FDA 510(k) clearance in March 2025 and is expected to be commercialized with Zimmer Biomet implants in early 2027. Additionally, Monogram is developing a fully autonomous version of the technology with the potential to significantly increase safety, efficiency and outcomes, as well as additional applications beyond TKA. Upon closing of the proposed transaction, Zimmer Biomet expects to have a clear pathway to become the first and only company in orthopedics to offer a fully autonomous surgical robot. 'Monogram's technology is a major leap forward, demonstrating our commitment to becoming the boldest and broadest innovator in surgical robotics and navigation,' said Ivan Tornos, Chairman, President and Chief Executive Officer of Zimmer Biomet. 'Upon closing, our customer-centric portfolio will consist of the most comprehensive and flexible technology ecosystem to support the varying preferences of a vast array of surgeons – now and into the future. With Monogram's proprietary technology, Zimmer Biomet has the potential to become the first company to deliver fully autonomous capabilities and redefine both the standard of care and the future of orthopedic surgery.' The proposed transaction expands Zimmer Biomet's extensive suite of orthopedic robotics, enabling solutions and analytics to address the needs of surgeons pre-, intra- and post-operatively. Zimmer Biomet's broad portfolio features imageless robotics through its ROSA platform; a licensed CT-based handheld robot; mixed reality navigation; AI-based surgical navigation; and a pathway to advanced semi- and fully autonomous robotics capabilities. Increasingly, Zimmer Biomet is uniquely positioned to solve for the diverse preferences of a wide range of surgeons globally and address multiple styles of surgical techniques, such as CT and non-CT; robotic and non-robotic; and manual, surgeon-centered methods or semi- or fully autonomous technologies. The ROSA platform, which is the cornerstone of Zimmer Biomet's robotics offering, is rapidly approaching 2,000 installations worldwide and is a market leader outside of the United States. Zimmer Biomet is committed to continuing to advance the ROSA platform and is investing in a robust R&D pipeline featuring several new product and software applications expected between now and 2027. This includes ROSA Knee with OptimiZe, which has been submitted to the FDA and 510(k) clearance is anticipated later this year, as well as ROSA Posterior Hip and the full commercial launch of ROSA Shoulder. 'Since our inception, we have been singularly focused on advancing orthopedic robotics with technology designed to safely, efficiently and accurately support surgeons with total knee arthroplasty,' said Benjamin Sexson, Chief Executive Officer of Monogram. 'We are thrilled by the opportunity to add our technology to Zimmer Biomet's leading portfolio of surgical robotics, navigation solutions and trusted implants and to benefit from their deep industry expertise and global scale.' Zimmer Biomet plans to fund the proposed transaction through a combination of cash on the balance sheet and other available debt financing sources. Zimmer Biomet expects to maintain a strong balance sheet and to continue to support its stated capital allocation priorities. Zimmer Biomet believes this proposed transaction and the CVR structure is compelling from both a strategic and financial standpoint. The acquisition of Monogram further strengthens Zimmer Biomet's capabilities in robotics, one of the fastest growing segments within orthopedics. Zimmer Biomet expects the acquisition will contribute to revenue growth in 2027 and beyond by improving the Company's robotic knee adoption in the U.S., increasing share of wallet through reaching new customers with a broader product range, and expanding the Company's industry-leading global knee offerings. Zimmer Biomet anticipates the acquisition will be neutral to adjusted earnings per share in 2025, 2026 and 2027, and accretive in 2028 and beyond. Additionally, the transaction is projected to generate high-single digit return on invested capital (ROIC) by year five, with an increasing contribution thereafter. Closing of the proposed transaction is subject to receipt of required regulatory approvals, approval by Monogram's common stockholders and other customary closing conditions, and the merger is anticipated to close later this year. Advisors Morgan Stanley & Co. LLC is serving as exclusive financial advisor to Zimmer Biomet and Hogan Lovells US LLP is serving as legal advisor. Wells Fargo Securities, LLC is serving as exclusive financial advisor to Monogram and Duane Morris LLP is serving as legal advisor. About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation. For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit or follow on LinkedIn at or X/ Twitter at About Monogram Technologies Monogram Technologies (NASDAQ: MGRM) is an AI-driven robotics company focused on improving human health, with an initial focus on orthopedic surgery. The Company is developing a product solution architecture to enable patient-optimized orthopedic implants at scale by combining 3D printing, advanced machine vision, AI and next-generation robotics. To learn more, visit Cautionary Statement Regarding Forward-Looking Statements This release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Zimmer Biomet and Monogram, which involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, forward-looking statements can be identified by the use of forward-looking terms such as "anticipate," "estimate," "believe," "continue," "could," "intend," "may," "plan," "potential," "predict," "should," "will," "expect," "are confident that," "objective," "projection," "forecast," "goal," "guidance," "outlook," "effort," "target," "would" or the negative of these terms or other comparable terms. Forward-looking statements in this release include, among other things, statements about the potential benefits of the proposed transaction; anticipated accretion and growth rates; plans, objectives, beliefs, expectations and intentions of the board of directors of Zimmer Biomet, Zimmer Biomet management, the board of directors of Monogram and Monogram management; the financial condition, results of operations and businesses of Zimmer Biomet and Monogram; the possibility that the milestones associated with the contingent value rights are achieved in part or at all; and the anticipated timing of closing of the proposed transaction. These forward-looking statements are based on certain assumptions and analyses made by Zimmer Biomet and Monogram in light of Zimmer Biomet's and Monogram 's experience and Zimmer Biomet's and Monogram 's perception of historical trends, current conditions and expected future developments, as well as other factors Zimmer Biomet and Monogram believe are appropriate in the circumstances. These forward-looking statements also are based on the current expectations and beliefs of the respective managements of Zimmer Biomet and Monogram and are subject to certain known and unknown risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, among other things, (i) risks related to the satisfaction of the conditions to closing the proposed transaction (including the failure to obtain necessary regulatory approvals) in the anticipated timeframe or at all, including uncertainties as to whether the stockholders of Monogram will approve the proposed transaction and the possibility that the proposed transaction does not close; (ii) risks related to the possibility that competing offers or acquisition proposals for Monogram will be made; (iii) the occurrence of any event, change or other circumstances that could give rise to the termination of the definitive transaction agreement relating to the proposed transaction, including in circumstances which would require Monogram to pay a termination fee; (iv) risks related to the ability to realize the anticipated benefits of the proposed transaction, including the possibility that the expected benefits from the proposed transaction will not be realized or will not be realized within the expected time period; (v) the risk that the businesses will not be integrated successfully; (vi) risks relating to changing demand for Zimmer Biomet's and Monogram's existing products; (vii) risks relating to the achievement, in part or at all, of the revenue and other milestones necessary for the payment of any contingent value rights; (viii) disruption from the proposed transaction making it more difficult to maintain business and operational relationships, including with customers, vendors, service providers, independent sales representatives, agents or agencies, and Monogram's ability to attract, motivate or retain key executives, employees and other associates; (ix) risks related to the proposed transaction diverting Zimmer Biomet's and/or Monogram's managements' attention from the ongoing business operations of their respective business; (x) negative effects of this announcement or the consummation of the proposed transaction on the market price of Zimmer Biomet's and/or Monogram's common stock and on Zimmer Biomet's and/or Monogram's operating results; (xi) significant transaction costs; (xii) unknown liabilities; (xiii) the risk of litigation, including stockholder litigation, and/or regulatory actions, including any conditions, limitations or restrictions placed on approvals by any applicable governmental entities, related to the proposed transaction; and (xiv) (A) other risks and uncertainties discussed in Zimmer Biomet's and Monogram's respective Annual Reports on Form 10-K for the fiscal year ended December 31, 2024 and their subsequent Quarterly Reports on Form 10-Q (in particular, the risk factors set forth under the headings 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in such Annual Reports and Quarterly Reports), and (B) other risk factors identified from time to time in other filings with the U.S. Securities and Exchange Commission (the 'SEC'). Filings with the SEC are available on the SEC's website at The list of factors that may affect actual results and the accuracy of forward-looking statements is illustrative and is not intended to be exhaustive. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Zimmer Biomet and Monogram undertake no obligation to update any of these forward-looking statements as the result of new information or to reflect events or circumstances after the date of this communication or to reflect actual outcomes, expect as required by law, and expressly disclaim any obligation to revise or update any forward-looking statement to reflect future events or circumstances. Additional Information about the Proposed Transaction and Where to Find It In connection with the proposed transaction, Monogram intends to file relevant materials with the SEC, including preliminary and definitive proxy statements relating to the proposed transaction. The definitive proxy statement will be mailed to Monogram's stockholders in connection with the proposed transaction. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS OF MONOGRAM ARE URGED TO READ THE PRELIMINARY AND DEFINITIVE PROXY STATEMENTS AND ALL RELEVANT DOCUMENTS TO BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION OR INCORPORATED BY REFERENCE IN THE PROXY STATEMENT WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders may obtain free copies of these documents (if and when they are available) and other related documents filed with the SEC at the SEC's web site at and on Monogram's' website at In addition, the proxy statement and other documents may be obtained free of charge by directing a request to Monogram Technologies Inc., ATTN: Investor Relations, 3913 Todd Lane, Suite 307, Austin, TX, 78744 telephone: (512) 399-2656. Participants in the Solicitation Zimmer Biomet and Monogram and their respective directors and executive officers and other members of management and employees, under SEC rules, may be deemed participants in the solicitation of proxies from the stockholders of Monogram in connection with the proposed transaction. Information regarding Zimmer Biomet's directors and executive officers can be found in Zimmer Biomet's definitive proxy statement on Schedule 14A for the 2025 Annual Meeting of Stockholders, filed with the SEC on April 14, 2025 and subsequent statements of beneficial ownership on file with the SEC. Information regarding Monogram's directors and executive officers can be found in Monogram's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was filed with the SEC on March 12, 2025 and subsequent statements of beneficial ownership on file with the SEC. These documents are available free of charge at the SEC's web site at on Zimmer Biomet's website at and on Monogram's website at Additional information regarding the interest of Monogram's participants in the solicitation of Monogram's stockholders, which may, in some cases, be different than those of Monogram's stockholders generally, will be set forth in the proxy statement related to the proposed transaction described above and other relevant materials to be filed with the SEC if and when they become available.
Yahoo
08-07-2025
- Business
- Yahoo
ISRG Expands Installed Base, But Is Utilization Keeping Pace?
Intuitive Surgical ISRG continues to expand its global dominance in robotic-assisted surgery with a 15% year-over-year increase in da Vinci system installations, bringing its global installed base to more than 10,000 units. In the first quarter of 2025, the company placed 367 da Vinci systems — including 147 of the next-gen da Vinci 5 — amid strong U.S. demand. However, installations outside the country remained unchanged year over year, reflecting healthcare budget constraints in markets like Germany, Japan and the United Kingdom. While Intuitive Surgical's recurring revenues, now 85% of the total revenues, remain robust, a critical metric — utilization — reveals a key tension. Overall, procedures grew 17% year over year, yet average system utilization rose just 2% across the multiport platforms. SP and Ion platforms posted stronger utilization increases of 26% and 5% respectively, supported by focused adoption strategies and new clearances. The limited growth in core platform utilization raises questions about the ROI of hospitals post-installation, particularly in constrained capital environments. Management acknowledged this dynamic, noting efforts to drive training, site enablement, and digital adoption to boost throughput. Additionally, da Vinci 5's Force Feedback and case insight tools, though early in rollout, are beginning to demonstrate measurable value in clinical outcomes and surgeon proficiency. ISRG's installed base expansion remains strong, especially in the United States. However, modest system utilization growth suggests that procedural ramp-up may lag deployments in some markets. Long-term growth will require more than system placements; it hinges on improving per-system productivity, proving clinical differentiation, and navigating financial headwinds that may shift hospital ROI expectations. Stryker SYK reported record-breaking Mako installations in the first quarter of 2025, both in the United States and globally, driven by sustained momentum in orthopedics and increased procedural demand. The new Mako 4 SmartRobotics system, launched this year, features a smaller OR footprint and improved integration with its latest Q Guidance system, streamlining setup and intraoperative workflows. Management cited high utilization rates for installed units globally, particularly in knee and hip procedures, where Mako continues to drive share gains. The company also noted progress toward launching Mako Spine later in 2025 and Mako Shoulder in early 2026, expanding its robotic footprint across specialties. With a strong capital order book and robust procedural volume, Stryker expects the Mako franchise to be a key contributor to its 8.5-9.5% organic growth target. Zimmer Biomet's ZBH ROSA robotics platform saw ongoing adoption in knee procedures, but results were more muted. While ROSA volume-based placements contributed to a mix shift versus outright sales, ROSA was mentioned as central to ZBH's robotic strategy in 2025. The company emphasized the growing uptake of cementless knee and hip implants, including the Oxford Partial Cementless Knee, which complements robotic workflows. Though specific ROSA installation figures weren't disclosed, the system remains integral to ZBH's ASC and digitization strategy. Management cited increased commercial focus and expanded surgical capabilities as key growth drivers, but acknowledged tariffs and ongoing pressure on operating margins as near-term headwinds. Shares of ISRG have gained 2.4% in the year-to-date period against the industry's decline of 7.7%. Image Source: Zacks Investment Research From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 64.35, above the industry average. But, it is still lower than its five-year median of 72.21. ISRG carries a Value Score of D. Image Source: Zacks Investment Research The Zacks Consensus Estimate for Intuitive Surgical's 2025 earnings implies a 6.8% rise from the year-ago period's level. Image Source: Zacks Investment Research The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Stryker Corporation (SYK) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Business Wire
02-07-2025
- Business
- Business Wire
Redwire Successfully Deploys the Most Powerful Roll-Out Solar Arrays Ever Built, Prepares for Major Delivery in Fourth Quarter
JACKSONVILLE, Fla.--(BUSINESS WIRE)--Redwire Corporation (NYSE: RDW), a global leader in aerospace and defense technology solutions, today announced that it has successfully completed the first deployment test for one of its Roll-Out Solar Arrays (ROSA) for the lunar Gateway's Power and Propulsion Element (PPE). Powered by PPE and Redwire's trailblazing ROSAs, the Gateway will represent the pinnacle of solar electric propulsion technology, a key capability not just for future exploration missions to the Moon and Mars, but for national security platforms as well. The Gateway ROSAs will generate an unprecedented 60kW - making these the most powerful ROSAs ever built. With this robust supply of power, Gateway will offer extensive capabilities for sustained exploration and research in deep space, potentially enabling ambitious activities such as resource extraction and utilization, while also providing peaceful space domain awareness and enhancing astronaut safety. Redwire was contracted by Maxar, the prime contractor for PPE, to develop two ROSA wings. The pair of PPE ROSAs will undergo additional testing in the coming months as Redwire prepares to deliver the ROSA wings to Maxar in the fourth quarter of 2025. 'Redwire is proud to be contributing critical infrastructure for PPE and the Gateway mission, and we are grateful for the trust of our customer Maxar and the dedicated teams that are delivering this important hardware. These ROSAs represent a significant technology achievement that will propel human spaceflight into a bold future,' said Adam Biskner, Redwire President of Space Systems. Redwire hosted a number of Gateway's industry and international partners to witness the unveiling of the most powerful ROSAs. Leaders from Maxar, Northrop Grumman, the European Space Agency, the Consulate General of Canada, the Japan Aerospace Exploration Agency, and the United Arab Emirates' Mohammed Bin Rashid Space Centre (MBRSC), participated in the event and voiced uniform and unwavering support for the importance of the Gateway to deep space exploration of the Moon and Mars. To watch a replay of the remarks, visit 'The unprecedented global coalition supporting Gateway is providing more than 60% of its funding, creating a massive savings for the American taxpayer. Moreover, gaining experience with a large spacecraft supporting surface operations will create invaluable experience to ensure that a future mission to Mars is safe and successful. Gateway will ensure that we do not cede the benefits of our international partnerships on Earth, or exploration leadership on the Moon and Mars to China.' added Mike Gold, Redwire President of Civil and International Space. About Redwire Redwire Corporation (NYSE:RDW) is an integrated aerospace and defense company focused on advanced technologies. We are building the future of aerospace infrastructure, autonomous systems and multi-domain operations leveraging digital engineering and AI automation. Redwire's approximately 1,300 employees located throughout the United States and Europe are committed to delivering innovative space and airborne platforms transforming the future of multi-domain operations. For more information, please visit
North Wales Chronicle
11-06-2025
- Health
- North Wales Chronicle
Surgeons from Europe observe robotic knee surgery at Ysbyty Gwynedd
The surgeons, from Poland, Slovakia, Romania and the United Kingdom have been observing the operations carried out by Consultant Orthopaedic Surgeon Muthu Ganapathi. Ysbyty Gwynedd, in Bangor, has been pioneering robotic knee replacements since 2022 and is the only NHS hospital in Wales to offer this type of surgery. Mr Ganapathi along with colleagues Agustin Soler, Koldo Azura, Amir Azam and Ashok Goel have now carried out more than 250 robotic knee replacements using the ROSA robotic system. Mr Ganapathi said: 'There has been a paradigm shift in how a knee replacement is carried out. 'Traditionally the bone cuts were made with a 'one shape fit all' approach but there is increasing recognition that a personalised approach maybe better. With this type of approach, the bone cuts are personalised to match as closely to the individual patient's knee shape. The precision of the robot allows us to do the personalised bone cuts.' The ROSA being used by surgeons Mr Ganapathi and Mr Soler during a procedure in theatres at Ysbyty Gwynedd. (Image: BCUHB) 'With this personalised approach the recovery seems to be faster and less painful compared to traditional knee replacements.' Sion Quinn, Clinical Lead for Trauma and Orthopaedic Physiotherapy at Ysbyty Gwynedd, said: 'Since the establishment of robotic surgery we have seen patients recovering faster with less pain after their knee replacements. 'Within the NHS we are always looking at ways to improve the patient experience and with the introduction of these robotic knees we have seen improvement in patient outcomes.' MORE NEWS How much was spent on failed Denbighshire Leisure sale – full cost breakdown Man 'trapped' in vehicle taken to hospital after St Asaph crash Last year, Zimmer Biomet (ROSA robot) recognised Ysbyty Gwynedd as an official training centre for robotic knee replacements for surgeons across the UK and Europe which has led to interest further afield in this type of procedure. The use of the robot has also created further benefits by establishing an industry funded advanced Hip and Knee Robotic Fellowship role at Ysbyty Gwynedd. This provides the opportunity for senior surgeons across the UK to work with the robotic team for six months and get trained in robotics before applying for their Consultant posts. Orthopaedic Surgeon, Ashok Singh, who is the current Robotic Fellow has already completed his Orthopaedic training in London and chose this fellowship to advance his skills. He said: 'I was attracted to this Fellowship as the skill sets it offered was unique for this fellowship. It isn't just the robotic technique I am having the opportunity to learn it is also other techniques such as the direct anterior approach which is a minimally invasive technique for total hip arthroplasty and Oxford Uni knees. 'I am really enjoying this Fellowship, the personalised knee replacement technique with robotics has been extremely beneficial and I have seen excellent results. So, it's something I will definitely be using in my practice as I develop in my career.' Mr Ganapathi added: 'We are delighted with the feedback we are receiving from our Fellows since it was established last year – it's been such a positive experience for them and us as Consultants. 'The ROSA has helped us put Ysbyty Gwynedd and the Health Board on the map for innovation and how we are constantly trying to improve our service and ensure we always have the best outcomes for our patients.'
Yahoo
02-06-2025
- Business
- Yahoo
AITX's RAD Receives RIO™ Expansion Orders from Major Client
Latest Orders Part of Ongoing National Rollout of AI-Powered Security Solutions by Leading Logistics Provider Detroit, Michigan, June 02, 2025 (GLOBE NEWSWIRE) -- Artificial Intelligence Technology Solutions, Inc. (the 'Company') (OTCPK:AITX), a global leader in AI-driven security and productivity solutions for enterprise clients, along with its wholly owned subsidiary Robotic Assistance Devices, Inc. (RAD), today announced that a major global logistics client has placed additional orders for multiple RIO 360 solar-powered security towers, each equipped with SARA™ (Speaking Autonomous Responsive Agent), AITX's proprietary Agentic AI platform. These new deployments on the West Coast represent a continuation of the client's ongoing national expansion of RAD's security technology and software. This latest order underscores the growing confidence major organizations have in RAD's solutions to address evolving security challenges at scale. By extending their deployment of RIO units across additional facilities, the client demonstrates a commitment to leveraging advanced AI and automation for greater site protection, operational efficiency, and standardized incident response nationwide. The RIO 360 units will be deployed at the client's distribution and logistics centers, where they serve as a reliable and cost-effective alternative to traditional manned security posts. Each unit is connected to SARA in the cloud, enabling real-time intelligent monitoring, automated voice talk-downs to deter suspicious activity, immediate notifications to security personnel, and comprehensive incident reporting. This seamless integration allows the RIO units to deliver consistent site monitoring and rapid response, helping the client strengthen facility security while optimizing operational resources. 'We are proud to support this client's nationwide growth with solutions that deliver proven results in challenging environments,' said Mark Folmer, CPP, PSP, President of RAD. 'Their continued adoption of RIO and SARA highlights the value and impact that AI-driven security can bring to complex logistics operations. We look forward to helping more organizations realize similar benefits as they modernize their security strategies.' SARA's growing adoption across a variety of industries and sectors reflects a broader shift toward AI-powered, autonomous security solutions. With each new deployment, SARA further establishes its role as an essential technology for organizations seeking to automate routine monitoring, accelerate incident response, and maintain consistency across multiple sites. The momentum seen in this rollout signals increasing demand for intelligent security platforms that deliver reliable performance in real-world environments. Sitting atop a standard RIO 360 configuration are dual ROSA™ units. ROSA is a multiple award-winning, compact, self-contained, portable, security and communication solution that can be installed and activated in about 15 minutes. ROSA's AI-driven security analytics include human, firearm, vehicle detection, license plate recognition, responsive digital signage and audio messaging, and complete integration with RAD's software suite notification and autonomous response library. Two-way communication is optimized for cellular, including live video from ROSA's high-resolution, full-color, always-on cameras. RAD has published six Case Studies detailing how ROSA has helped eliminate instances of theft, trespassing and loitering at retail centers, hospital campuses, multi-family communities, car rental locations and construction sites across the country. AITX, through its subsidiary, Robotic Assistance Devices, Inc. (RAD), is redefining the nearly $50 billion (US) security and guarding services industry1 through its broad lineup of innovative, AI-driven Solutions-as-a-Service business model. RAD solutions are specifically designed to provide cost savings to businesses of between 35%-80% when compared to the industry's existing and costly manned security guarding and monitoring model. RAD delivers these tremendous cost savings via a suite of stationary and mobile robotic solutions that complement, and at times, directly replace the need for human personnel in environments better suited for machines. All RAD technologies, AI-based analytics and software platforms are developed in-house. The Company's operations and internal controls have been validated through successful completion of its SOC 2 Type 2 audit, reinforcing the Company's credibility with enterprise and government clients who require strict data protection and security compliance. RAD has a prospective sales pipeline of over 35 Fortune 500 companies and numerous other client opportunities. RAD expects to continue to attract new business as it converts its existing sales opportunities into deployed clients generating a recurring revenue stream. Each Fortune 500 client has the potential of making numerous reorders over time. About Artificial Intelligence Technology Solutions (AITX)AITX is an innovator in the delivery of artificial intelligence-based solutions that empower organizations to gain new insight, solve complex challenges and fuel new business ideas. Through its next-generation robotic product offerings, AITX's RAD, RAD-R, RAD-M and RAD-G companies help organizations streamline operations, increase ROI, and strengthen business. AITX technology improves the simplicity and economics of patrolling and guard services and allows experienced personnel to focus on more strategic tasks. Customers augment the capabilities of existing staff and gain higher levels of situational awareness, all at drastically reduced cost. AITX solutions are well suited for use in multiple industries such as enterprises, government, transportation, critical infrastructure, education, and healthcare. To learn more, visit and or follow Steve Reinharz on X @SteveReinharz. CAUTIONARY DISCLOSURE ABOUT FORWARD-LOOKING STATEMENTSThe information contained in this publication does not constitute an offer to sell or solicit an offer to buy securities of Artificial Intelligence Technology Solutions, Inc. (the 'Company'). This publication contains forward-looking statements, which are not guarantees of future performance and may involve subjective judgment and analysis. The information provided herein is believed to be accurate and reliable, however the Company makes no representations or warranties, expressed or implied, as to its accuracy or completeness. The Company has no obligation to provide the recipient with additional updated information. No information in this publication should be interpreted as any indication whatsoever of the Company's future revenues, results of operations, or stock price. ### Steve Reinharz949-636-7060@SteveReinharz 1
